Clinical Proof-of-concept Study on Rapid Immune Modulating Effects

NCT05364710 — Not applicable, Unknown, 24 participants, Natural Immune Systems Inc

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

Clinical Poof-of-concept Study on Rapid Immune Modulating Effects

RegistryNCT05364710
StatusUnknown
PhaseNot applicable
Study typeInterventional; randomized, crossover, masking: triple, basic science
Enrollment24 (Estimated)
SponsorNatural Immune Systems Inc (Other)
ConditionsImmune Surveillance
InterventionsTransfer factor from colostrum ultrafiltrate (Dietary supplement)
Datesstart 2022-05-07, primary completion 2022-12-01 (estimated), completion 2023-06-01 (estimated), first posted 2022-05-06, last updated 2022-05-13
Locations1 site in United States

Related Papers Related Patents Related Grants Related Experts
All trials for Immune Surveillance All trials of Transfer factor from colostrum ultrafiltrate

-Summary

Clinical-proof-of concept study, comparing the acute immune impacts of of 2 doses of a novel blend of supplements to a placebo. This study involves twenty-four participants, composed of healthy adults, who will be taking a placebo and 2 different doses of the blend at different times. Testing for immune status and cytokine levels will be conducted to determine the acute impact of the blend on immune function as compared to the placebo.

Expand all sections  ·  Collapse all

+Detailed description

Clinical-proof-of-concept study comparing the acute immune effects of 2 doses of a nutraceutical blend, and a placebo. The nutraceutical blend is based on a transfer factor isolated from cow colostrum ultrafiltrate.

24 subjects will participate in a placebo-controlled, randomized, double-blinded, cross-over study design, wherein they will be taking placebo, dose 1, and dose 2, each separated by a 1-week washout period.

Blood samples are taken 1 hour after participants arrive; the dose is then administered. Samples are taken 1 hour, 2 hours, and 24 hours following administration. At each blood sample collection, a spit sample will also be taken for salivary IgA testing.

A series of immune panels will be used to determine the acute impacts on immune surveillance, immune cell activation status, immune cell priming, and cytokine profiles.

+Arms and interventions

ArmTypeInterventionsDescription
Group AExperimentalDietary Supplement: Transfer factor from colostrum ultrafiltrateCrossover study: Participants will be consuming placebo on a clinic day at least 1 week prior to a clinic day where he/she will consume the active intervention.
Group BExperimentalDietary Supplement: Transfer factor from colostrum ultrafiltrateCrossover study: Participants will be consuming the active intervention on a clinic day at least 1 week prior to a clinic day where he/she will consume placebo.
  • Transfer factor from colostrum ultrafiltrate (Dietary supplement): Proteins that confer immune protection, isolated from cow colostrum ultrafiltrate and used to promote immune health and surveillance.

+Outcome measures

Primary outcomes

  • Immune communication [2 hours]: Observation of changes in serum cytokine levels

Secondary outcomes

  • Immune Surveillance and Alertness [2 hours]: Observation of changes in immune cell trafficking and status of immune cell alertness, ie. the changes in immune cell populations and activation following administration.

Other outcomes

  • Immune responsiveness [2 hours]: Ex vivo immune challenges, observing the capabilities of anti-bacterial and anti-viral defenses. Additionally, mucosal immune protection as determined by salivary IgA, defensins, and transferrin changes.

+Eligibility

Sex: All, ages: 18 Years to 75 Years, accepts healthy volunteers

Inclusion Criteria:

* Healthy adults
* Veins easy to see in one or both arms
* Willing to comply with study procedures, including
* Maintaining a consistent diet and lifestyle routine throughout the study;
* Consistent habit of bland breakfast on days of clinic visits
* Abstaining from exercising on and nutritional supplements on the morning of a study visit;
* Abstaining from use of coffee, tea, and soft drinks for at least one hour prior to a clinic visit;
* Abstaining from music, candy, gum, computer/cell phone use, during clinic visits

Exclusion Criteria:

* Previous major gastrointestinal surgery
* Taking anti-inflammatory medications on a daily basis
* Currently experiencing intense stressful events/life changes
* Currently in intensive athletic training (such as marathon runner)
* Currently taking antipsychotic medications such as clozapine, Risperdal, Abilify, Zyprexa or Seroquel
* An unusual sleep routine
* Unwilling to maintain a constant intake of supplements over the duration of the study
* Anxiety about having blood drawn
* People of childbearing potential: Pregnant, nursing, or trying to become pregnant
* Known food sensitivities related to ingredients in active test product placebo Prescription medication evaluated on a cas-by-case basis

+Locations (1)

FacilityCityCountryStatus
NIS LabsKlamath Falls, OregonUnited StatesRecruiting